State Street
CTKB icon

State Street’s Cytek Biosciences CTKB Stock Holding History

State Street’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Sell
2,566,121
-1,557,627
-38% -$6.65M ﹤0.01% 2645
2026
Q1 		$18M Sell
4,123,748
-23,216
-0.6% -$110K ﹤0.01% 2290
2025
Q4 		$20.9M Buy
4,146,964
+62,596
+2% +$291K ﹤0.01% 2246
2025
Q3 		$14.2M Sell
4,084,368
-89,395
-2% -$336K ﹤0.01% 2424
2025
Q2 		$14.2M Sell
4,173,763
-208,411
-5% -$695K ﹤0.01% 2378
2025
Q1 		$17.6M Sell
4,382,174
-128,204
-3% -$664K ﹤0.01% 2208
2024
Q4 		$29.3M Buy
4,510,378
+342,877
+8% +$2.04M ﹤0.01% 2001
2024
Q3 		$23.1M Buy
4,167,501
+194,369
+5% +$1.1M ﹤0.01% 2124
2024
Q2 		$22.2M Sell
3,973,132
-142,727
-3% -$857K ﹤0.01% 2121
2024
Q1 		$27.6M Buy
4,115,859
+118,090
+3% +$934K ﹤0.01% 2034
2023
Q4 		$36.5M Buy
3,997,769
+220,226
+6% +$1.39M ﹤0.01% 1873
2023
Q3 		$20.9M Buy
3,777,543
+370,108
+11% +$2.97M ﹤0.01% 2156
2023
Q2 		$29.1M Buy
3,407,435
+1,348,163
+65% +$12.1M ﹤0.01% 1999
2023
Q1 		$18.9M Buy
2,059,272
+20,927
+1% +$225K ﹤0.01% 2265
2022
Q4 		$20.8M Buy
2,038,345
+8,092
+0.4% +$109K ﹤0.01% 2218
2022
Q3 		$29.9M Buy
2,030,253
+304,433
+18% +$3.95M ﹤0.01% 1943
2022
Q2 		$18.5M Buy
1,725,820
+405,162
+31% +$4.03M ﹤0.01% 2307
2022
Q1 		$14.2M Buy
1,320,658
+1,048,629
+385% +$14.2M ﹤0.01% 2627
2021
Q4 		$4.44M Buy
272,029
+64,590
+31% +$1.35M ﹤0.01% 3297
2021
Q3 		$4.44M Buy
+207,439
New +$4.88M ﹤0.01% 3303

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

State Street's CTKB Position: Q2 2026 in Review

State Street reduced its Cytek Biosciences (CTKB) stake by 38% in Q2 2026, selling an estimated $6.65M and leaving 2,566,121 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2645.

State Street first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $36.5M in Q4 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • State Street held 2,566,121 shares of Cytek Biosciences worth $11.4M as of Q2 2026.
  • State Street sold 1,557,627 Cytek Biosciences shares in Q2 2026, an estimated $6.65M.
  • Cytek Biosciences made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2645 holding.
  • State Street first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • State Street's Cytek Biosciences position peaked at $36.5M in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.